Market News Call

Investors Alert: MannKind Corporation (NASDAQ:MNKD), Mast Therapeutics Inc (NYSEMKT:MSTX), Exelixis, Inc. (NASDAQ:EXEL)

Lakeway, NY — (MARKET NEWS CALL) — 01/02/2016—, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Mast Therapeutics Inc (NYSEMKT:MSTX), Exelixis, Inc. (NASDAQ:EXEL), MannKind Corporation (NASDAQ:MNKD).

Mast Therapeutics Inc (NYSEMKT:MSTX)’s shares gained 3.27% to $0.41. The company, on Feb. 1, 2016, reported that its product candidate AIR001, a sodium nitrite solution being developed for treatment of heart failure with preserved ejection fraction (HFpEF), has been selected by the Heart Failure Clinical Research Network (HFN) for evaluation in a 100-patient, multicenter, randomized, double-blind, placebo-controlled, Phase 2 clinical trial known as the Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF (INDIE-HFpEF) study.

Should Investors Buy MSTX After The Recent Development? Find Out Here

Exelixis, Inc. (NASDAQ:EXEL)’s shares jumped 3.90% to $4.79. The company, on Feb. 1, 2016, announced positive overall survival (OS) results from METEOR, the phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with advanced renal cell carcinoma (RCC) who have experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor (TKI). In a second interim analysis for OS, a secondary endpoint of the trial, the results showed a highly statistically significant and clinically meaningful increase in OS for patients randomized to cabozantinib as compared to everolimus. Ongoing study monitoring did not identify any new safety signals. Exelixis intends to present these data at a medical meeting later this year.

Is EXEL Going To Rise or Fall After Today’s Price Action? Find Out Here

MannKind Corporation (NASDAQ:MNKD)’s shares gained 3.78% to $1.03. The company will host a conference call to discuss Company developments at 5:00 PM (Eastern Time) on Feb. 3, 2016.

Can Traders Buy MNKD After The Solid Rally? Get Free Trend Analysis Here

Additionally, Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP, on Jan. 25, 2016, announce that a federal class action lawsuit has been filed against MannKind Corp. and several officers and directors for acts taken during the period of Aug. 10, 2015 through Jan. 5, 2016 (the “Class Period”).

About is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.

Tags: , , ,

Comments are closed.